Precigen, Inc. (PGEN): Long-Term Debt
$93.17M
As of 2025-12-31
$93.88M
As of 2026-06-30
+29.2%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.17M | n/a | 2026-03-25, Balance as of period end |
| 2024-12-31 | $0 | n/a | 2026-03-25, Balance as of period end |
| No annual figure between 2022-12-31 and 2024-12-31. | |||
| 2022-12-31 | $43.22M | -76.0% | 2023-03-06, Balance as of period end |
| 2021-12-31 | $179.93M | n/c | 2023-03-06, Balance as of period end |
| 2020-12-31 | $171.88M | -21.2% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $217.99M | +3.0% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $211.69M | n/m | 2020-03-02, Balance as of period end |
| 2017-12-31 | $8.04M | +1.1% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $7.95M | -6.8% | 2018-03-01, Balance as of period end |
| 2015-12-31 | $8.53M | -17.8% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $10.37M | +527.3% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $1.65M | n/a | 2015-03-02, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Precigen, Inc. (PGEN) | 2025-12-31 | $93.17M | n/a |
| BioAge Labs, Inc. (BIOA) | 2024-12-31 | $8.50M | n/a |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $27.13M | -6.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2024-12-31 | $8.65M | -21.4% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $1.65M | n/a |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $0 | n/a |
| uniQure N.V. (QURE) | 2025-12-31 | $71.92M | +8.9% |
| Verastem, Inc. (VSTM) | 2024-12-31 | $40.72M | +1.6% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $0 | -100.0% |
Compare PGEN, BIOA, EMMA, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗